Sign in
4

Changes in Ownership

Kymera Therapeutics, Inc. Filed Acc 0001415889-24-019440

Director sold 453,960 shares at an average $38.21 ($17,346,919)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Booth Bruce · Director

Table I: Non-derivative

10 lines
Date Transaction Shares Price Value Owned after D/I
2024-07-09 Sale : show line 1 in the form 10b5-1 −24,449 $35.57 $869,651 4,523,951 I
2024-07-09 Sale : show line 2 in the form 10b5-1 −28,718 $36.40 $1,045,335 4,495,233 I
2024-07-09 Sale : show line 3 in the form 10b5-1 −41,763 $37.41 $1,562,354 4,453,470 I
2024-07-09 Sale : show line 4 in the form 10b5-1 −183,868 $38.48 $7,075,241 4,269,602 I
2024-07-09 Sale : show line 5 in the form 10b5-1 −96,386 $39.26 $3,784,114 4,173,216 I
2024-07-09 Sale : show line 6 in the form 10b5-1 −5,133 $35.57 $182,581 796,889 I
2024-07-09 Sale : show line 7 in the form 10b5-1 −6,030 $36.40 $219,492 790,859 I
2024-07-09 Sale : show line 8 in the form 10b5-1 −8,769 $37.41 $328,048 782,090 I
2024-07-09 Sale : show line 9 in the form 10b5-1 −38,606 $38.48 $1,485,559 743,484 I
2024-07-09 Sale : show line 10 in the form 10b5-1 −20,238 $39.26 $794,544 723,246 I
Open-market sales · 453,960 sh · avg $38.21 · $17,346,919
Loading xslF345X05/form4-07092024_090724.xml…